Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Immunity of Minhai PCV13 in Healthy Children
NCT06210737Phase 4Completed
- Sponsor
- Beijing Minhai Biological
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Pneuminvac in pneumonia, pneumococcal infection, sponsored by Beijing Minhai Biological. Started Sep 2019; status: completed.
02
Drugs
Pneuminvac
03
Conditions
pneumoniapneumococcal infection
Beyond the preview
Go deeper on NCT06210737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210737.